Thyrotropin Controversy in Subclinical Thyroid Disorders

Area of Science:

• Endocrinology
• Clinical Chemistry

Background:

• Subclinical thyroid disorders (STDs) are prevalent endocrine conditions, affecting approximately 9.4% of the Indian population, with higher incidence in females.
• Diagnosis often relies on biochemical markers like thyrotropin (TSH), triiodothyronine (T3), and thyroxine (T4), which can be challenging due to asymptomatic presentations and vague symptoms.

Purpose of the Study:

• To address the ongoing controversy surrounding the diagnosis and treatment of subclinical hypothyroidism (SCH) and subclinical hyperthyroidism (SHT).
• To highlight the complexities in interpreting thyroid function tests (TFTs) due to various interfering factors and methodological variations.

Main Methods:

• Review of diagnostic criteria for STDs, including interpretation of TSH, FT4, and FT3 levels.
• Discussion of factors influencing TFT results, such as assay interference, biotin intake, and timing of tests.
• Analysis of the association between STDs and other health conditions like cardiovascular diseases and metabolic syndrome.

Main Results:

• TSH levels alone are often insufficient for diagnosing SCH and SHT, necessitating consideration of T3, T4, FT4, and FT3 levels.
• Assay interference from factors like HAMA, THAAbs, and biotin can lead to spurious TFT results and misdiagnosis.
• Progression of SCH to overt hypothyroidism is influenced by initial TSH levels, thyroid peroxidase antibodies (TPO), family history, and environmental factors.

Conclusions:

• Consensus on TSH diagnostic thresholds requires large-scale randomized clinical and epidemiological studies with diverse populations.
• Avoid immediate treatment for TSH levels between 4-10 mIU/L or 0.1-0.5 mIU/L without confirmatory tests and consideration of other TFTs.
• Sequential testing from the same laboratory and time, alongside FT3 and FT4 stability, aids accurate diagnosis and treatment decisions in STDs.